Vasculitis & polymyalgia rheumatica
High level of serum complement 3 is a risk factor for vascular stenosis progression in Takayasu arteritis (TA) patients receiving tocilizumab: a prospective observational study
Authors' conclusion
47.4% of TA patients treated with tocilizumab would suffer VSP. A high C3 level is a risk factor for VSP in TA patients receiving tocilizumab
Study context
- Population
- Patients with Takayasu arteritis (TA) receiving tocilizumab, East China Takayasu Arteritis cohort
- Participants
- 38 patients
- Exposure
- Patients with vascular stenosis progression (VSP) vs patients without VSP
- Outcome
- Vascular stenosis progression (VSP) on magnetic resonant angiography or CT angiography, and its risk factors
Methodological detailsmultivariate Cox regression
- Multivariate Cox regression
Main finding
As reported in the abstract
Patients with VSP
18
47.4%
Baseline C3 level independently associated with VSP (multivariate Cox), HR
7.05
95% CI 1.50–33.07p = 0.013
C3 cut-off value
1.22 g/L
Observational data: associations, not effects.
Further findings
New and worsened vascular ischemic symptoms and events (VISE) during follow-up
- Patients with new VISE
- seven
- Patients with worsened VISE
- three
Time to VSP occurrence · during follow-up
- Median period for VSP occurrence
- 6.9 months
Baseline C3, patients with vs without VSP
- Patients with VSP showed higher levels of baseline C3 than those without VSP
Original publication
High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study. Arthritis Res Ther. Published 2 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →